![Robert Gunning](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : - $ au 31/08/2026
Robert W.
Gunning is currently Principal Accounting Officer, VP & Controller at NewAmsterdam Pharma Co. NV since 2026.
Formerly, Mr. Gunning was Controller at Altimmune, Inc. in 2026 and Vice President-Finance & Controller at Y-mAbs Therapeutics, Inc. from 2022 to 2026.
Mr. Gunning completed undergraduate education at Pace University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/09/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Comptroller/Controller/Auditor | 10/08/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| ALTIMMUNE, INC. | Comptroller/Controller/Auditor | 01/07/2026 |
| YMAS THER | Comptroller/Controller/Auditor | 01/04/2026 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Pace University
 Pace University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Altimmune, Inc.
 Altimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
NewAmsterdam Pharma Co. NV
 NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
